**SPECIAL FEATURES**

**CCR Translations**

323  BAP1tism of a Tumor Suppressor
Scott E. Woodman
See article p. 408

**Molecular Pathways**

326  Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
William C. Dougall

**Perspective**

336  New Challenges in Endpoints for Drug Development in Advanced Melanoma
Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, and John M. Kirkwood

**Review**

342  Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Michaela R. Reagan and Irene M. Ghobrial

**HUMAN CANCER BIOLOGY**

350  Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Brooke E. Sylvester, Dezhegao Huo, Andrey Krahmstov, Jing Zhang, Rana V. Smiling, Sope Olugbile, Blase N. Polite, and Olufunmilayo I. Olopade

360  A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Rajasubramaniam Shanmugam, Padmaja Gade, Anique Wilson-Weekes, Hamid Sayar, Attaya Suvannasankha, Chirayu Goswami, Lang Li, Sushil Gupta, Angela A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Dhananjaya V. Kalvakolanu, and Scott Boswell

370  Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Rossitza Lazova, Robert L. Camp, Vincent Klump, Summay F. Siddiqui, Ravi K. Amaravadi, and John M. Pawelek

380  Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Hui-Fung Yuen, Ka-Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osama Sharaf Eldin, Koen O’Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, and Mohamed El-Tanani

390  Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
Yu Sasaki, Hiroaki Takeda, Takeshi Sato, Tomohiko Otii, Shosichi Nishiie, Ko Naogino, Daisuke Iwano, Takao Yatoa, Kazuya Yoshizawa, Hideki Saito, Yasuhiro Tanaka, and Sumio Kawata

400  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa A. Rybicki, Mohammed S. Orloff, and Charis Eng

**CANCER THERAPY: PRECLINICAL**

408  Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Kneass, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, and J. William Harbour
See commentary p. 323

417  Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
Sascha Dietrich, Oliver H. Krämer, Esther Hahn, Claudia Schäfer, Thomas Giese, Michael Hess, Theresa Tretter, Michael Rieger, Jennifer Hüllein, Thorsten Zenz, Anthony D. Ho, Peter Dregger, and Thomas Luft
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

Bexarotene via CBP/p300 Induces Suppression of NF-kB-Dependent Cell Growth and Invasion in Thyroid Cancer
Audrey Cras, Béatrice Politis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
Andreas Wicki, Christoph Buchlitz, Annette Orleth, Reto Ritschard, Inke Albrecht, Richard Herrmann, Gerhard Christofori, and Christoph Mamot

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
Michele Cioffi, Jorge Dorado, Patrick A. Baeuerle, and Christopher Heeschen

CPTH6, a Thiazole Derivative, Induces Histone Hypoaetylation and Apoptosis in Human Leukemia Cells
Daniela Trisciuoglio, Ylenia Ragazzoni, Andrea Pelosi, Marianna Desideri, Simone Carradori, Chiara Gabrielli, Giovanna Maresca, Riccardo Nescatelli, Daniela Secchi, Adriana Bolasco, Bruna Bizzarri, Chiara Cavaliere, Igea D'Agnano, Patrizia Filetici, Lucia Ricci-Vitiani, Maria Giulia Rizzo, and Donatella Del Bufalo

Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Hailing Lu, Gregory N. Dietsch, Maura-Ann H. Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Sun, Vernon C. Maino, Katherine E. Henderson, James Jeffry Howbert, Mary L. Disis, and Robert M. Hershberg

Clinical Cancer Research
ABOUT THE COVER

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.